NCT06353386 2026-04-17
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
5 trialsNCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT04086485 2026-04-07
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06785636 2026-04-07
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
NCT02484404 2026-03-25
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting